[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1126075T1 - Αντισωμα που περιλαμβανει μια c-τελικη επεκταση ελαφρας αλυσιδας που περιλαμβανει γλουταμινη, συζευγματα αυτου, και μεθοδοι και χρησεις - Google Patents

Αντισωμα που περιλαμβανει μια c-τελικη επεκταση ελαφρας αλυσιδας που περιλαμβανει γλουταμινη, συζευγματα αυτου, και μεθοδοι και χρησεις

Info

Publication number
CY1126075T1
CY1126075T1 CY20231100264T CY231100264T CY1126075T1 CY 1126075 T1 CY1126075 T1 CY 1126075T1 CY 20231100264 T CY20231100264 T CY 20231100264T CY 231100264 T CY231100264 T CY 231100264T CY 1126075 T1 CY1126075 T1 CY 1126075T1
Authority
CY
Cyprus
Prior art keywords
glutamine
antibody
conjugates
methods
light chain
Prior art date
Application number
CY20231100264T
Other languages
English (en)
Inventor
Pavel Strop
Chetana Rao-Naik
Xiaodi DENG
Paul O. Sheppard
Patrick G. HOLDER
Sayumi YAMAZOE
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1126075T1 publication Critical patent/CY1126075T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ένα αντίσωμα έχει μία επέκταση που περιέχει γλουταμίνη στο C-άκρο μιας ελαφράς αλυσίδας αυτού, που το καθιστά κατάλληλο για σύζευξη μέσω διαμιδίωσης με τη διαμεσολάβηση τρανσγλουταμινάσης.
CY20231100264T 2018-11-30 2023-06-02 Αντισωμα που περιλαμβανει μια c-τελικη επεκταση ελαφρας αλυσιδας που περιλαμβανει γλουταμινη, συζευγματα αυτου, και μεθοδοι και χρησεις CY1126075T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773708P 2018-11-30 2018-11-30
PCT/US2019/062913 WO2020112588A1 (en) 2018-11-30 2019-11-25 Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses

Publications (1)

Publication Number Publication Date
CY1126075T1 true CY1126075T1 (el) 2023-11-15

Family

ID=68916605

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20231100264T CY1126075T1 (el) 2018-11-30 2023-06-02 Αντισωμα που περιλαμβανει μια c-τελικη επεκταση ελαφρας αλυσιδας που περιλαμβανει γλουταμινη, συζευγματα αυτου, και μεθοδοι και χρησεις

Country Status (25)

Country Link
US (1) US20220016260A1 (el)
EP (1) EP3886914B1 (el)
JP (1) JP7389803B2 (el)
KR (1) KR20210098488A (el)
CN (1) CN113453725A (el)
AU (1) AU2019386945A1 (el)
BR (1) BR112021010060B1 (el)
CA (1) CA3121131A1 (el)
CY (1) CY1126075T1 (el)
DK (1) DK3886914T3 (el)
EA (1) EA202191518A1 (el)
ES (1) ES2943474T3 (el)
FI (1) FI3886914T3 (el)
HR (1) HRP20230500T1 (el)
HU (1) HUE062089T2 (el)
IL (1) IL283576B2 (el)
LT (1) LT3886914T (el)
MX (1) MX2021005874A (el)
PL (1) PL3886914T3 (el)
PT (1) PT3886914T (el)
RS (1) RS64205B1 (el)
SG (1) SG11202105565UA (el)
SI (1) SI3886914T1 (el)
SM (1) SMT202300159T1 (el)
WO (1) WO2020112588A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6322996B1 (en) 1994-08-23 2001-11-27 Drug Delivery System Institute, Ltd. Protein modification method
WO2000043492A2 (en) 1999-01-22 2000-07-27 Smithkline Beecham Corporation Method of site specific labeling of proteins and uses therefor
JP4118462B2 (ja) 1999-07-19 2008-07-16 株式会社リコー 携帯電子機器
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
EP1471938A4 (en) 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
MX342007B (es) 2003-05-14 2016-09-09 Immunogen Inc Composicion de farmaco conjugado.
WO2004106939A2 (en) 2003-06-03 2004-12-09 Paul Scherrer Institut Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides
UY28424A1 (es) 2003-07-22 2005-02-28 Schering Ag Anticuerpos rgi y usos de los mismos.
AU2004316290C1 (en) 2003-11-06 2012-02-02 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
CN1889979B (zh) 2003-12-10 2012-09-19 米德列斯公司 Ip-10抗体及其用途
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US7778814B2 (en) 2004-03-30 2010-08-17 Siemens Aktiengesellschaft Method and device for simulating an automation system
NZ560414A (en) 2005-02-18 2011-04-29 Medarex Inc Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
KR20070115967A (ko) 2005-02-18 2007-12-06 메다렉스, 인코포레이티드 전립선 특이 막 항원(ｐｓｍａ)에 대한 인간 모노클로날항체
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
EP2982379A1 (en) 2005-07-01 2016-02-10 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
KR20080056167A (ko) 2005-09-26 2008-06-20 메다렉스, 인코포레이티드 씨디70에 대한 인간 모노크로날 항체
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
WO2007067991A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to o8e
NZ568551A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to Fucosyl-GM1 and methods using anti-Fucosyl-GM1
SI1957539T1 (sl) 2005-12-08 2013-05-31 Medarex, Inc. Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba
PE20080316A1 (es) 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
PE20080102A1 (es) 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
PL2486941T3 (pl) 2006-10-02 2017-08-31 E. R. Squibb & Sons, L.L.C. Przeciwciała ludzkie wiążące cxcr4 i ich wykorzystanie
MX2009005776A (es) 2006-12-01 2009-06-10 Medarex Inc Anticuerpos humanos que se enlazan al cd 22 y sus usos.
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
JP5868593B2 (ja) 2007-07-17 2016-02-24 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
BRPI0816014A8 (pt) 2007-10-01 2018-06-19 Bristol Myers Squibb Co anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina
JPWO2010002042A1 (ja) 2008-07-04 2011-12-22 国立大学法人九州大学 タンパク質ラベル化用酵素基質
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
JP5870400B2 (ja) 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
BR112014006703A8 (pt) 2011-09-20 2018-01-09 Spirogen Sarl "pirrolobenzodiazepinas
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
PE20141791A1 (es) 2012-02-13 2014-11-19 Bristol Myers Squibb Co Compuestos de enediino, conjugados de los mismos y sus usos y metodos
US9333271B2 (en) 2012-05-30 2016-05-10 University Of Massachusetts Coated up-conversion nanoparticles
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
BR112015019432A2 (pt) 2013-02-14 2017-08-22 Bristol Myers Squibb Co Compostos de tubulisina, métodos de produção e uso
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
CA2919583C (en) 2013-07-31 2018-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates
SG11201601047SA (en) 2013-08-14 2016-03-30 Univ Rice William M Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
CN106459981A (zh) 2013-12-23 2017-02-22 酵活有限公司 包含c端轻链多肽延伸的抗体和缀合物及其使用方法
JP6498773B2 (ja) 2015-01-14 2019-04-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
EP3245207B1 (en) 2015-01-14 2019-08-21 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
WO2016144608A1 (en) * 2015-03-10 2016-09-15 Bristol-Myers Squibb Company Antibodies conjugatable by transglutaminase and conjugates made therefrom
BR112017027258A2 (pt) 2015-06-23 2018-08-28 Bristol-Myers Squibb Company dímeros de benzodiazepina macrocíclicos, conjugados dos mesmos, preparação e usos
ES2855998T3 (es) * 2015-08-07 2021-09-27 Merck Patent Gmbh Etiqueta transglutamina para bioconjugación específica de sitio eficiente
EP3355934A1 (en) 2015-10-02 2018-08-08 Bristol-Myers Squibb Company Transglutaminase variants for conjugating antibodies
EP3500574B1 (en) 2016-08-19 2021-11-24 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor

Also Published As

Publication number Publication date
HRP20230500T1 (hr) 2023-07-21
US20220016260A1 (en) 2022-01-20
PL3886914T3 (pl) 2023-05-08
FI3886914T3 (fi) 2023-05-26
KR20210098488A (ko) 2021-08-10
BR112021010060A2 (pt) 2021-08-24
IL283576A (en) 2021-07-29
JP7389803B2 (ja) 2023-11-30
BR112021010060B1 (pt) 2024-03-12
AU2019386945A1 (en) 2021-07-22
JP2022513686A (ja) 2022-02-09
PT3886914T (pt) 2023-05-05
EP3886914B1 (en) 2023-03-29
LT3886914T (lt) 2023-05-25
RS64205B1 (sr) 2023-06-30
ES2943474T3 (es) 2023-06-13
EA202191518A1 (ru) 2021-10-04
CA3121131A1 (en) 2020-06-04
WO2020112588A1 (en) 2020-06-04
IL283576B1 (en) 2023-03-01
SMT202300159T1 (it) 2023-07-20
IL283576B2 (en) 2023-07-01
EP3886914A1 (en) 2021-10-06
HUE062089T2 (hu) 2023-09-28
CN113453725A (zh) 2021-09-28
MX2021005874A (es) 2021-07-16
SG11202105565UA (en) 2021-06-29
SI3886914T1 (sl) 2023-06-30
DK3886914T3 (da) 2023-07-03

Similar Documents

Publication Publication Date Title
MX2019013387A (es) Dominio de union a antigeno.
CY1126075T1 (el) Αντισωμα που περιλαμβανει μια c-τελικη επεκταση ελαφρας αλυσιδας που περιλαμβανει γλουταμινη, συζευγματα αυτου, και μεθοδοι και χρησεις
CY1124408T1 (el) ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ
CY1125440T1 (el) Αντι-τιμ-3 αντισωματα και συνθεσεις
CY1126053T1 (el) Ενωσεις και μεθοδοι για στοχευμενη αποικοδομηση υποδοχεα ανδρογονων
CY1124714T1 (el) Συζευγματα πυρρολοβενζοδιαζεπινης-αντισωματος
EA201691827A1 (ru) Конкретные участки для модификации антител с целью получения иммуноконъюгатов
CY1125053T1 (el) Συζευγματα πυρρολοβενζοδιαζεπινων
PH12021551425A1 (en) Bifunctional anti-pd-1/sirpa molecule
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CL2018003809S1 (es) Luz de automóvil.
PE20230381A1 (es) Proteina de union a rgma
CO2020009737A2 (es) Composiciones de edb que se dirigen a il-12
CY1124648T1 (el) Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου
CY1124244T1 (el) Παραλλαγματα αντισωματος
AR115599A1 (es) Método y aparato para la preparación de un bien de ensilado y proceso de ensilaje
EA202190653A1 (ru) Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях
CL2020000999A1 (es) Dispositivo de inspección con desplazamiento no motorizado de tuberías de fluido
CY1121816T1 (el) Αγκυρα με διαταξη γωνιακης ρυθμισης
CL2019001113S1 (es) Componente de retención.
CO2023009965A2 (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina
TR202019577U4 (tr) Abajur bağlanti aparatinda yeni̇li̇k
AR115295A1 (es) USO DE ANTICUERPOS QUE UNEN A IL-1b
JP1722046S (ja) 自動車
EA202091752A1 (ru) Композиции il-12, нацеленные на edb